CompletedPhase 3

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

China204 participantsStarted 2022-09-27

Plain-language summary

It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular hypertension in Chinese subjects. It is planned that 240 subjects (120 in each group) will be randomly assigned to receive OPC-1085EL or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Gender: Unlimited
✓. Hospitalization status: Outpatients
✓. Age: 20-80 years old
✓. Subjects with both eyes diagnosed as primary open angle glaucoma or ocular hypertension.
✓. IOP: After 4 weeks treatment with 0.005% latanoprost, the unilateral eye with a pre-dose IOP from 18 mmHg to \<30 mmHg, and IOP \<30 mmHg in the contralateral eye.

Exclusion criteria

✕. Subjects with a best-corrected visual acuity ≤ 0.2.
✕. Subject with any secondary glaucoma such as exfoliative or pigmented glaucoma.
✕. Subjects who cannot stop using contact lenses during the trial.
✕. Subjects who are judged by investigators to be at risk when receiving carteolol hydrochloride or 0.005% latanoprost as monotherapy.
✕. Subjects who are allergic to any ingredients in carteolol or latanoprost.

What they're measuring

evaluate pre-dose intraocular pressure change from baseline to week 8

Timeframe: baseline；week 8

Trial details

NCT IDNCT05583474

SponsorOtsuka Beijing Research Institute

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-11-22

View on ClinicalTrials.gov More Open Angle Glaucoma or Ocular Hypertension trials